Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Here's Why resTORbio Fell Over 83% Today

TheMotleyFool

0 0

Here's Why resTORbio Fell Over 83% TodayPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by David Maisel: https://img.theapi.app/temp/0e9d087d-988e-4397-b7cf-6049e2776769.png

Shares of resTORbio (NASDAQ: TORC) fell over 83% today after the company reported that its lead drug candidate, RTB101, failed a late-stage clinical trial evaluating its potential to prevent respiratory illness in adults over 65. The company has discontinued development in that indication but will continue exploring its potential as a treatment for Parkinson's disease.

While resTORbio reminded investors that it ended September with $117 million in cash, that did little to stop a mass exodus from the company's shares. Investors adjusted the company's market valuation from over $320 million to roughly $50 million on the news.

As of 10:49 a.m. EST, the pharma stock was down 82.8%.

Source Fool.com

Like: 0

TORC

Teilen